News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Investing.com South Africa Market update
This article announces the filing of a Form 8K by MediciNova Inc. on August 19. It provides basic information about the filing and mentions the stock symbol MNOV along with its current performance. The content is primarily a brief news alert from Investing.com.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …
Inovio Pharmaceuticals Inc. (INO) stock surged by 19.99% following a Jefferies upgrade to Buy, betting on a positive FDA decision for its INO-3107 treatment for recurrent respiratory papillomatosis. The company's Q2 loss per share improved significantly, and management believes current cash reserves can fund …
Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …
Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …
Sharemaestro market context Price below Trend Line 52 weeks -64.8% · Next-week setup negative 34.0%Zacks Research has upgraded Inovio Pharmaceuticals (NASDAQ:INO) to a "strong-buy" rating. This upgrade comes as the company reported a quarterly loss of $0.07 per share, beating analyst expectations, and anticipates an FDA decision for its key product INO-3107 by October 30, 2026. The company …
MediciNova (MNOV) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss and improving from a $0.07 loss a year ago. The company also exceeded revenue estimates, posting $0.46 million against a $0.15 million consensus, though its …
MediciNova (NASDAQ:MNOV) exceeded quarterly earnings expectations, reporting a loss of $0.05 per share against an estimated $0.06 loss, and revenues of $0.46 million, significantly above the $0.07 million forecast. Despite the positive earnings surprise, the company experienced a slight dip in share price to …
This article provides a Q2 earnings snapshot for MediciNova. No further details are available in the provided content.
MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …
Seven analysts have issued a consensus "Hold" rating for Inovio Pharmaceuticals (NASDAQ:INO), with an average 12-month price target of $3.25. The company recently reported a quarterly loss of $0.07 per share, outperforming analyst expectations, while institutional investors own approximately 26.79% of its stock. Shares …
Inovio (INO) discussed its Q2 2026 financial results and provided an update on its lead candidate, INO-3107, which has a PDUFA date of October 30, 2026. The company highlighted progress in regulatory reviews, commercial launch preparations, and positive Phase III results for VGX-3100 from …
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer …
Sharemaestro market context Price below Trend Line 52 weeks -64.8% · Next-week setup negative 34.0%INOVIO announced its second-quarter 2026 financial results, highlighting the advancement of the FDA's review of its BLA for INO-3107 for Recurrent Respiratory Papillomatosis with a target PDUFA date of October 30, 2026. The company also reported positive Phase 3 results for VGX-3100 in cervical …
Inovio Pharmaceuticals Inc is projected to report a loss of 22 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation.
MediciNova Inc is projected to report a loss of 6 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article provides more details on this financial forecast.
MediciNova, Inc. (MNOV) is expected to announce its Q2'26 earnings on August 14, with an estimated revenue of $75.00 thousand USD and an anticipated EPS of ($0.06) USD. The company's past reported revenues and EPS for previous quarters are also provided for comparison.
RA Capital Management and its affiliates, including Peter Kolchinsky and Rajeev Shah, have reported a beneficial ownership of 10,666,523 shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which represents 9.99% of the company's common stock. This ownership includes 7,220,384 direct shares and warrants exercisable for …
Inovio Pharmaceuticals (INO.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors and analysts with a specific date to anticipate the company's financial performance update.
MediciNova (MNOV) is expected to release its Q2 2026 earnings after market close on Thursday, August 13th, with analysts projecting a loss of $0.06 per share and $75,000 in revenue. The company previously reported a loss of $0.05 per share, beating expectations, and matched …
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 8,454,797 shares of Inovio Pharmaceuticals (INO) common stock, representing a 10.3% stake, as of June 30, 2026. This includes Fidelity Small Cap Growth Fund holding 5,632,660 shares, or 6.8% of the outstanding common …
Inovio Pharmaceuticals (NASDAQ: INO) is expected to announce its Q2 2026 earnings on Wednesday, August 12th, with analysts forecasting a loss of $0.25 per share and revenue of $0.533 million. The company's stock opened at $0.66, near its 52-week low, and institutional investors have …
INOVIO (NASDAQ: INO) announced it will release its second-quarter 2026 financial results after the market close on August 12, 2026. Following the release, the biotechnology company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide …
Inovio Pharmaceuticals Inc. (INO) shares fell 4.84% to $0.66 on Tuesday, despite an overall positive trading session for the stock market. The NASDAQ Composite Index and the Dow Jones Industrial Average both saw significant gains. This decline broke a two-day winning streak for Inovio's …
INOVIO (NASDAQ: INO) announced it will release its second quarter 2026 financial results after market close on August 12, 2026. The company will host a live, listen-only conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and …
Piper Sandler has reiterated its Buy rating on Inovio Pharmaceuticals (INO.US) but has lowered its price target for the stock to $4. This adjustment reflects an updated valuation for the company.
Inovio has initiated an underwritten public offering of common stock and accompanying warrants, or pre-funded warrants in lieu of common stock. Piper Sandler is the sole manager for this offering, which includes a 30-day option for underwriters to purchase up to an additional 15% …
This article displays the "Price to book forward" for MediciNova, Inc. (NASDAQ: MNOV) on TradingView. It provides financial data for the company, accessible through various features on the platform. The main content shows the period, value, and change metrics for this financial indicator.
Search by ticker symbol or company name and select a result to open its chart.